Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 3/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 3/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6010271 | 1.00 | SLC7A5 (0.46) | SLC7A5ESR1ESR2TRPV1MME | |
| SCHEMBL6009856 | 0.88 | CYP1A2 (0.46) | SLC7A5FOLH1 | |
| SCHEMBL6009878 | 0.88 | CYP1A2 (0.46) | SLC7A5FOLH1 | |
| SCHEMBL7431337 | 0.81 | OPRM1 (0.44) | SLC7A5ESR1ESR2TRPV1MME | |
| SCHEMBL14906484 | 0.80 | TRPV1 (0.50) | SLC7A5ESR1TRPV1 | |
| SCHEMBL6010274 | 0.78 | SLC7A5 (0.43) | SLC7A5ESR1ESR2TRPV1MME | |
| SCHEMBL14357545 | 0.78 | SLC7A5 (0.51) | SLC7A5ESR1ESR2POLBCA2 | |
| SCHEMBL30736141 | 0.78 | SLC7A5 (0.51) | SLC7A5ESR1ESR2MMEACE | |
| SCHEMBL6010256 | 0.76 | SLC7A5 (0.46) | SLC7A5ESR1ESR2TRPV1MME | |
| SCHEMBL2542276 | 0.75 | SLC7A5 (0.56) | SLC7A5ESR1ESR2TRPV1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | SEIWA KASEI COMPANY, LIMITED (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1584320-A1 | COSMETIC PREPARATION CONTAINING GLYCERYLAMINO ACID DERIVATIVE | Seiwa Kasei Company, Limited (JP) | 2005-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | GLA, GPKOW, CUTA | SLC7A5 1780/4885ESR1 4422/4885ESR2 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.